免疫检查点疗法在脓毒症治疗中的研究进展OA
Research progress of immune checkpoint therapy in the treatment of sepsis
免疫抑制被认为是导致脓毒症发生和病死的重要原因,由于脓毒症病理生理机制复杂,目前没有专门治疗脓毒症的药物被批准上市.临床前和临床研究表明,免疫细胞检查点如程序性细胞死亡受体 1、细胞毒性T淋巴细胞抗原 4、T细胞免疫球蛋白黏蛋白 3 和分化簇 134 可通过介导宿主免疫激活和免疫抑制之间的良好平衡,在脓毒症的病理生理过程中发挥重要作用,免疫细胞检查点药物可以改善先天免疫和适应性免疫细胞功能,并显著提高宿主存活率.因此,基于免疫检查点的免疫疗法在脓毒症治疗中具有巨大的潜力,本文综述了免疫检查点疗法在脓毒症治疗中的临床前,临床研究进展和应用前景.
Immunosuppression is considered to be an important cause of sepsis and death.Due to the complex pathophysiological mechanism of sepsis,there is still no drug specifically used to treat sepsis approved.Pre-clinical and clinical studies have shown that immune cell checkpoints such as programmed cell death protein 1,cytotoxic T lymphocyte-associated antigen-4,B and T lymphocyte attenuator,T cell immunoglobulin and mucin domain 3,and cluster of differentiation 134 can play an important role in the pathophysiological process of sepsis by mediating a good balance between host immune activation and immunosuppression.Therapeutic drugs designed to block immune cell checkpoints can improve innate and acquired immune cell functions and significantly improve host survival.Therefore,immune checkpoint based immunotherapy has great potential in the treatment of sepsis.This article reviews the pre-clinical/clinical research progress and application prospects of immune checkpoint therapy in the treatment of sepsis.
王渊学;许珊珊;安宏;石耀辉
甘肃中医药大学附属医院药学部,甘肃 兰州 730030兰州大学第二医院药剂科,甘肃 兰州 730030兰州大学第二医院急诊科,甘肃 兰州 730030甘肃省渭源县中医院普外科,甘肃渭源 743000
医药卫生
脓毒症免疫检查点免疫抑制免疫疗法
SepsisImmune checkpointImmunosuppressionImmunotherapy
《中国医药科学》 2025 (13)
31-37,7
甘肃省自然科学基金(21JR11RA106).
评论